These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 35781166)

  • 1. Pembrolizumab plus lenvatinib as first-line therapy for patients with mismatch repair-proficient advanced endometrial cancer: A United States-based cost-effectiveness analysis.
    Liu K; Zhu Y; Zhou Y; Zhang Y; Zhu H
    Gynecol Oncol; 2022 Sep; 166(3):582-588. PubMed ID: 35781166
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of lenvatinib plus pembrolizumab versus chemotherapy for recurrent mismatch repair-proficient endometrial cancer after platinum-based therapy.
    Dioun S; Chen L; De Meritens AB; St Clair CM; Hou JY; Khoury-Collado F; Pua T; Hershman DL; Wright JD
    Gynecol Oncol; 2024 Mar; 182():70-74. PubMed ID: 38262241
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost effectiveness of pembrolizumab plus lenvatinib compared with chemotherapy for treating previously treated advanced endometrial cancer in Sweden.
    Ralph L; Young K; Upadhyay N; Prabhu VS; Ljungcrantz C; Massaad R; Xu R; Giertz A; Merchant A; Orlowski R; Duska L
    J Med Econ; 2024; 27(1):483-491. PubMed ID: 38470404
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lenvatinib Plus Pembrolizumab vs. Chemotherapy in Pretreated Patients With Advanced Endometrial Cancer: A Cost-Effectiveness Analysis.
    Feng M; Chen Y; Yang Y; Li Q
    Front Public Health; 2022; 10():881034. PubMed ID: 35619813
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lenvatinib plus pembrolizumab in the patients with advanced previously treated endometrial cancer: A cost-effectiveness analysis in the United States and in China.
    Liao X; Wu Y; Lin D; Gu D; Luo S; Huang X; Xu X; Weng X; Lin S
    J Obstet Gynaecol Res; 2024 May; 50(5):881-889. PubMed ID: 38485235
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pembrolizumab and lenvatinib versus carboplatin and paclitaxel as first-line therapy for advanced or recurrent endometrial cancer: A Markov analysis.
    Ackroyd SA; Huang ES; Kurnit KC; Lee NK
    Gynecol Oncol; 2021 Aug; 162(2):249-255. PubMed ID: 34103196
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lenvatinib plus Pembrolizumab for Advanced Endometrial Cancer.
    Makker V; Colombo N; Casado Herráez A; Santin AD; Colomba E; Miller DS; Fujiwara K; Pignata S; Baron-Hay S; Ray-Coquard I; Shapira-Frommer R; Ushijima K; Sakata J; Yonemori K; Kim YM; Guerra EM; Sanli UA; McCormack MM; Smith AD; Keefe S; Bird S; Dutta L; Orlowski RJ; Lorusso D;
    N Engl J Med; 2022 Feb; 386(5):437-448. PubMed ID: 35045221
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of pembrolizumab plus chemotherapy for advanced endometrial cancer.
    Huo G; Song Y; Chen P
    J Gynecol Oncol; 2024 Apr; ():. PubMed ID: 38606826
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immune checkpoint inhibitors with chemotherapy for primary advanced mismatch repair-deficient endometrial cancer: A cost-effectiveness analysis.
    Kim J; Lim J; Lee SW; Park JY; Suh DS; Kim JH; Kim YM; Kim DY
    Gynecol Oncol; 2023 Dec; 179():106-114. PubMed ID: 37976756
    [TBL] [Abstract][Full Text] [Related]  

  • 10. First-Line Lenvatinib Plus Pembrolizumab or Everolimus versus Sunitinib for Advanced Renal Cell Carcinoma: A United States-Based Cost-Effectiveness Analysis.
    Zhu Y; Liu K; Ding D; Peng L
    Clin Genitourin Cancer; 2023 Jun; 21(3):417.e1-417.e10. PubMed ID: 36529626
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness analysis of lenvatinib plus pembrolizumab compared with chemotherapy for patients with previously treated mismatch repair proficient advanced endometrial cancer in China.
    Zheng Z; Yang L; Xu S; Zhu H; Cai H
    Front Pharmacol; 2022; 13():944931. PubMed ID: 36249813
    [No Abstract]   [Full Text] [Related]  

  • 12. Lenvatinib plus pembrolizumab in advanced recurrent endometrial cancer: A cost-effectiveness analysis.
    Barrington DA; Haight PJ; Calhoun C; Tubbs C; Cohn DE; Bixel KL
    Gynecol Oncol; 2021 Sep; 162(3):626-630. PubMed ID: 34148720
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness of pembrolizumab compared with chemotherapy in the US for women with previously treated deficient mismatch repair or high microsatellite instability unresectable or metastatic endometrial cancer.
    Thurgar E; Gouldson M; Matthijsse S; Amonkar M; Marinello P; Upadhyay N; Nwankwo C; Aguiar-Ibáñez R
    J Med Econ; 2021; 24(1):675-688. PubMed ID: 33866938
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analysis of East Asia subgroup in Study 309/KEYNOTE-775: lenvatinib plus pembrolizumab versus treatment of physician's choice chemotherapy in patients with previously treated advanced or recurrent endometrial cancer.
    Yonemori K; Fujiwara K; Hasegawa K; Yunokawa M; Ushijima K; Suzuki S; Shikama A; Minobe S; Usami T; Kim JW; Kim BG; Wang PH; Chang TC; Yamamoto K; Han S; McKenzie J; Orlowski RJ; Miura T; Makker V; Man Kim Y
    J Gynecol Oncol; 2024 Mar; 35(2):e40. PubMed ID: 38302725
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pembrolizumab Plus Chemotherapy as First-Line Treatment for Advanced Esophageal Cancer: A Cost-Effectiveness Analysis.
    Zhu Y; Liu K; Ding D; Zhou Y; Peng L
    Adv Ther; 2022 Jun; 39(6):2614-2629. PubMed ID: 35394255
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness of dostarlimab plus chemotherapy for primary advanced or recurrent endometrial cancer.
    Huo G; Song Y; Liu W; Guo H; Chen P
    Front Pharmacol; 2024; 15():1391896. PubMed ID: 38966552
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness analysis of pembrolizumab versus chemotherapy as first-line treatment in locally advanced or metastatic non-small cell lung cancer with PD-L1 tumor proportion score 1% or greater.
    She L; Hu H; Liao M; Xia X; Shi Y; Yao L; Ding D; Zhu Y; Zeng S; Shen L; Huang J; Carbone DP
    Lung Cancer; 2019 Dec; 138():88-94. PubMed ID: 31655368
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-Effectiveness Analysis of Pembrolizumab in Patients With Advanced Esophageal Cancer Based on the KEYNOTE-181 Study.
    Zhan M; Xu T; Zheng H; He Z
    Front Public Health; 2022; 10():790225. PubMed ID: 35309225
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase 3, randomized, open-label study of pembrolizumab plus lenvatinib versus chemotherapy for first-line treatment of advanced or recurrent endometrial cancer: ENGOT-en9/LEAP-001.
    Marth C; Tarnawski R; Tyulyandina A; Pignata S; Gilbert L; Kaen D; Rubio MJ; Frentzas S; Beiner M; Magallanes-Maciel M; Farrelly L; Choi CH; Berger R; Lee C; Vulsteke C; Hasegawa K; Braicu EI; Wu X; McKenzie J; Lee JJ; Makker V
    Int J Gynecol Cancer; 2022 Jan; 32(1):93-100. PubMed ID: 34799418
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of Pembrolizumab in Second-line Advanced Bladder Cancer.
    Sarfaty M; Hall PS; Chan KKW; Virik K; Leshno M; Gordon N; Moore A; Neiman V; Rosenbaum E; Goldstein DA
    Eur Urol; 2018 Jul; 74(1):57-62. PubMed ID: 29576265
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.